Joshua M. Hare, M.D.
Co-Founder and Chief Science Officer
Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the Founding Director of the university’s Interdisciplinary Stem Cell Institute (ISCI). Through his work with ISCI, Hare has made significant advances in the field of stem cell regenerative medicine, including the creation of relevant intellectual property.
A graduate of the University of Pennsylvania (1984) and the Johns Hopkins University School of Medicine (1988), Hare completed fellowships at Johns Hopkins and Brigham and Women’s Hospital in Boston, Ma. He served as a research fellow at Harvard University and is Board Certified in cardiovascular medicine. During his career, Hare has championed the field of allogeneic cell therapy, and he has conducted five clinical trials using allogenic cell therapy. Hare’s publications in the area of cell-based therapy are widely cited, and he holds six Investigational New Drug (IND) authorizations from the FDA for cell therapy drugs and treatments in patients with heart disease. Hare co-founded Longeveron as a means to bring his academic findings to patients with unmet medical needs.
Hare’s extensive list of accolades and professional experience includes:
Director, Interdisciplinary Stem Cell Institute (ISCI)
Louis Lemberg Professor of Medicine (cardiology), Leonard M. Miller School of Medicine, University of Miami
Professor of Biomedical Engineering
Professor of Molecular and Cellular Pharmacology
Professor of Cell Biology and Anatomy
Nominated in 2011 to the Association of American Physicians